Kiora Pharmaceuticals Inc (KPRX)

Nov 19, 2024

Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.

Nov 19, 2024

Nov 15, 2024

What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World

Nov 15, 2024

Nov 15, 2024

ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance

Nov 15, 2024

Nov 13, 2024

Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

Kiora Pharmaceuticals retains stock target and Buy rating on loss report - Investing.com UK

Nov 12, 2024

Nov 08, 2024

Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy

Nov 08, 2024

Nov 08, 2024

Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024

Nov 08, 2024

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile

Nov 08, 2024

Nov 08, 2024

Kiora Pharma Reports Strong Q3: $29M Cash Position, FDA Study Approval Boost Outlook | KPRX Stock News - StockTitan

Nov 08, 2024

Oct 30, 2024

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance

Oct 30, 2024

Oct 30, 2024

Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada

Oct 30, 2024

Oct 29, 2024

Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com

Oct 29, 2024

Oct 29, 2024

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance

Oct 29, 2024

Sep 25, 2024

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN

Sep 25, 2024

Sep 12, 2024

Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com

Sep 12, 2024

Sep 12, 2024

Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com

Sep 12, 2024

Aug 23, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright - Defense World

Aug 23, 2024

Aug 20, 2024

Kiora Pharmaceuticals director buys $19.8k in company stock By Investing.com - Investing.com Australia

Aug 20, 2024

Aug 20, 2024

Kiora Pharmaceuticals director buys $19.8k in company stock - Investing.com India

Aug 20, 2024

Aug 17, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 15.7% - Defense World

Aug 17, 2024

Aug 13, 2024

How To Buy Kiora Pharmaceuticals, Inc. Stock Online in August 2024 - Traders Union

Aug 13, 2024

Aug 09, 2024

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance

Aug 09, 2024

Aug 06, 2024

KPRXKiora Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Aug 06, 2024

Jul 30, 2024

Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe

Jul 30, 2024

Jul 30, 2024

Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment By Investing.com - Investing.com Canada

Jul 30, 2024

Jul 30, 2024

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile

Jul 30, 2024

Jul 24, 2024

HC Wainwright Brokers Decrease Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) - Defense World

Jul 24, 2024

Jul 24, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Price Target Increased to $10.00 by Analysts at HC Wainwright - Defense World

Jul 24, 2024

Jul 18, 2024

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 11.6% in June - Defense World

Jul 18, 2024

Jul 11, 2024

EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow

Jul 11, 2024

Jul 10, 2024

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - StockTitan

Jul 10, 2024

Jul 10, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 0.9% - Defense World

Jul 10, 2024

Jul 05, 2024

EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow

Jul 05, 2024

Jul 01, 2024

Kiora Pharmaceuticals appoints new board member By Investing.com - Investing.com

Jul 01, 2024

Jul 01, 2024

Sezzle Inc. former director Purcell sells shares worth over $1.29 million By Investing.com - Investing.com Australia

Jul 01, 2024

Jul 01, 2024

Vivakor nears acquisition of oil and gas logistics firms By Investing.com - Investing.com Canada

Jul 01, 2024

Jul 01, 2024

Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance - TipRanks

Jul 01, 2024

Jul 01, 2024

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - StreetInsider.com

Jul 01, 2024

Jun 25, 2024

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile

Jun 25, 2024

Jun 25, 2024

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory ... - StockTitan

Jun 25, 2024

Jun 24, 2024

CBRE to merge Project Management with Turner & Townsend By Investing.com - Investing.com UK

Jun 24, 2024

Jun 21, 2024

Global Payments shares price target cut by TD Cowen amid controversy By Investing.com - Investing.com

Jun 21, 2024

Jun 20, 2024

KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView

Jun 20, 2024